The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
ALL FUNDED GRANTS (1313)
Biomarker Development, 2015
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson's disease (PD) pathology. Such an agent will help (i) diagnose PD earlier, (ii) track pathology over time and (iii) monitor the efficacy of therapeutics reducing alpha-synuclein aggregates. The AC Immune team identified promising compounds that will be refined to target such a...
Access to Data and Biospecimens, 2015
The dysfunction of the systems responsible for the clearance of the protein alpha-synuclein plays a major role in Parkinson's disease (PD). The lysosome is an important sub-cellular compartment for alpha-synuclein disposal. Among the many lysosomal enzymes responsible for this degradation, major attention has been given to glucocerebrosidase (GCase). Several repo...
Therapeutic Pipeline Program, 2015
The abnormal aggregation of a protein known as alpha-synuclein appears to play a critical role in Parkinson's disease. This project will explore a new type of biomolecule, known as an aptamer, as a potential inhibitor of alpha-synuclein aggregation. We aim to discover an aptamer with anti-aggregation properties and then test its ability to thwart alpha-synuclein ag...
Target Validation, 2015
Chronic inflammation within the brain is emerging as a possible driver in the progression of Parkinson's disease (PD). Inflammasomes are protein complexes that function as sensors of cell stress and abnormal proteins, which drive inflammatory responses. This project aims to identify the contribution of the inflammasome in PD pathology and to ascertain the therapeut...
Researchers: Trent Woodruff, PhD
Research Grant, 2015
The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinson's disease. We have developed a novel modulator (VPAC2 agonist) that transforms adaptive immune activities from neurotoxic to neurotrophic (supporting growth). This project aims to determine pharmacokinetic and pharm...